David is the Co-founder, President and Chief Executive Officer of Frequency Therapeutics. He has over 20 years of entrepreneurial experience and has played an integral role in launching, building and operating many successful companies in the life sciences and other innovation sectors. Previously, David was the President and Chief Executive Officer of Entrega Bio, a PureTech Health company developing an innovative capsule technology to make injectable substances available orally.
David’s first MIT-based startup was Semprus BioSciences, a biomedical company that went from business concept, to FDA 510(k) clearance and CE Mark approval, to major acquisition in five years. Semprus won the MIT $100K Entrepreneurial Competition for its business plan to develop a novel platform technology for reducing complications associated with long-term medical device implants, such as thrombosis and microbial adhesion. David subsequently led Semprus’ closing on several large financings before the company was acquired by Teleflex in 2012. Prior to Semprus, David was a Senior Executive at the leading venture capital firm, Polaris Partners, where he was responsible for deal-sourcing and originating and the execution of Polaris’ investment in Athletes Performance, a leading training facility for NFL, MLB, NHL and NBA professional athletes.
David launched his career in the life sciences by co-founding LaunchCyte, an investment firm specialized in commercializing biomedical intellectual property, and was instrumental in launching six companies from Carnegie-Mellon University and the University of Pennsylvania, among others. David currently serves as Vice Chairman of the Board of Directors of MassBio. He serves as a trustee and Chair of the Audit Committee of Mt. Auburn Hospital, a Harvard Medical School facility, and holds a Board position with the Multiple Myeloma Research Foundation. David is on the advisory council for the National Outdoor Leadership School (NOLS) where he was part of expedition that summited Denali, North America’s high point. David earned an MBA at the MIT Sloan School of Management as an Alfred P. Sloan Fellow, an M.S. from Syracuse University and a B.A. from Denison University.
Michael is the Chief Operating Officer of Frequency Therapeutics. Prior to Frequency, he co-founded Catabasis Pharmaceuticals and served as Chief Scientific Officer, where his contributions helped create several potential new therapeutics and guide the company to an IPO in 2015. During his almost 30-year career, Michael has overseen 100’s of R&D programs and has brought more than 15 new therapeutics from discovery into clinical study to address muscular dystrophy, dyslipidemia, cancer and a variety of metabolic diseases. Michael is the former Senior Vice President of Research for Sirtris Pharmaceuticals, acquired by GlaxoSmithKline in 2008 after an IPO in 2007. He also led the metabolic disease therapeutic area at Pfizer’s Laboratories in La Jolla, California and has had leadership roles at Abbott Laboratories and Eli Lilly. Michael holds a Ph.D. in Chemistry from Case Western Reserve University and completed his post-doctoral study at Harvard University.
Chris is the Chief Scientific Officer and Co-founder of Frequency Therapeutics. Chris co-founded Semprus BioSciences and served as Chief Technology Officer through the company’s acquisition by Teleflex in 2012. He led the technology team in developing medical products with surface modifications designed to reduce infection and clotting, leading to FDA/CE Mark clearance. Prior to Semprus, Chris worked as a chemical engineer at Merck Research Labs. In 2011, he was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation. Chris has also been named to the TR35, the 35 innovators under 35 most likely to impact technology, and the Boston Business Journal 40 under 40. He is currently an Associate Adjunct Professor of Urology in the Yale School of Medicine. Chris holds a Ph.D. in Chemical Engineering from MIT, where he studied under Robert Langer, Sc.D., and a BSE from Princeton University.
Dana is the acting Chief Medical Officer for Frequency Therapeutics. Dana was formerly the Chief Medical Officer for FORUM Pharmaceuticals, where he supported the development of therapies for the treatment of cognitive impairment in schizophrenia and Alzheimer’s disease. He has aided in the development of a variety of potential therapeutics for Parkinson’s, ALS, Alzheimer’s, oncologic diseases, chronic pain, metabolic disorders and inflammatory conditions. He is a former Chief Medical Officer and Senior Vice President of Clinical Research, Medical Affairs and Development for Ascend Therapeutics and is the former Vice President of Clinical Research for Gilford Pharmaceuticals. Dana served on the staff of the National Institute of Health for five years. He has co-authored more than 100 publications and book chapters in both basic and clinical neurosciences. Dana earned his M.D. from Tufts University School of Medicine and trained in internal medicine at Harvard Medical School and neurology at the Johns Hopkins Hospital.
Raj is the Senior Vice President of Drug Development and Technical Operations for Frequency Therapeutics. Prior to joining Frequency, Raj was Vice President of Neurodegeneration Asset Development for Biogen. While at Biogen, he was instrumental in leading the CMC development for approval and commercialization for Tecfidera™, the leading oral therapy for MS. Before Biogen, he led development of imaging agents for Alzheimer’s at Avid Radiopharmaceuticals, which was acquired by Eli Lilly and Company in 2010. Previously, Raj has held key R&D positions at PerkinElmer and Diatide, which was acquired by Schering AG in 1999. During his 20 years in the pharmaceutical industry, he has worked on over 25 INDs and 6 NDAs, including two Fast Track programs, and provided program management for drug development in infectious disease, CNS, oncology, immunology and imaging. Raj holds a Ph.D. in Chemistry from Yale University and was an Anna Fuller post-doctoral fellow at MIT. Raj has also completed the Advanced Management Program from the Sloan School of Management at MIT.
Will is the Vice President of Biology and Regenerative Medicine and a Co-founder of Frequency Therapeutics. His scientific strategy leadership role at Frequency Therapeutics is backed by his expertise in stem cell biology, hearing, and neuroscience. During his doctoral research at MIT, Will elucidated the different stem cell types that exist within the inner ear. He later completed his post-doctoral studies at Harvard Medical School. Will’s hearing research has been published in multiple peer reviewed and invited journals, including the Journal of the Association for Research in Otolaryngology, Development, PLOS ONE, and Audiology Today. He was awarded the Harvard-MIT IDEA2 award for high-impact translational research and was an MIT $100K finalist. Will earned a Ph.D. from the Harvard-MIT Health Science and Technology Program within MIT and a B.S. in Biology from Tufts University.
Marc A. Cohen is the Chairman of Frequency Therapeutics. He is also a Co-founder and Executive Chairman of C4 Therapeutics. Additionally, Mr. Cohen is the Co-founder and Chief Executive Officer of Bublup, Inc.; Neuro Tennis, Inc.; and COBRO Ventures, Inc.; as well as the Co-founder and Chairman of Acetylon Pharmaceuticals, Inc. and OncoPep, Inc., two biotech companies spun out of Dana-Farber Cancer Institute and Harvard University. He was the Chief Executive Officer, Chairman and Co-founder of OPNET Technologies, Inc., a world leader in network and application performance management. OPNET was sold to Riverbed Technology in December 2012. He is currently a Trustee of the Dana-Farber Cancer Institute where he is focusing on accelerating translational research and increasing the flow of new therapies to patients. Mr. Cohen received a B.S. in Engineering from Harvard University and an M.S. in Electrical Engineering from Stanford University.
Tim Barberich is a founder of Sepracor, Inc., a publicly-traded and fully integrated research pharmaceutical company. He served as Sepracor’s Chief Executive Officer and Chairman for more than 20 years, where he grew revenues to more than a billion dollars through the successful partnering and commercialization of several products, including Allegra®, Clarinex®, Lunesta® and Xopenex®. In 2009, Sepracor, now known as Sunovion, was acquired by Dainippon Sumitomo to form one of the largest Japanese-based global pharmaceutical companies. Prior to founding Sepracor, Mr. Barberich spent 10 years as a senior executive at Millipore Corporation, a major supplier of research tools to the life sciences industry. He also served on the Board of Trustees of Boston Medical Center and the Pharmaceutical Research and Manufacturers’ Association. Mr. Barberich is a graduate of Kings College and holds a B.S. degree in Chemistry.
Marc Kozin is a Senior Advisor and former President of L.E.K. Consulting, a global management consulting firm. He is a career strategy consultant with 30 years of experience, both domestically and internationally, advising senior executives in life sciences to identify new growth opportunities, pursue highly-profitable mergers and acquisitions, and support sustained growth. He currently sits on the Boards of Endocyte, Inc., Flex Pharma, OvaScience and UFP Technologies in various capacities. Mr. Kozin also sits on the Boards of HealthCare Royalty and Helomics Corporation, both private companies. Additionally, Mr. Kozin has served on the Board of Governors at New England Medical Center for several years, and the Board of Directors for Dyax Corp., which acquired by Shire Plc for $5.9B in 2015. In 2002, Consulting Magazine named him one of the 25 most influential consultants in recognition of his leadership and results for clients. Mr. Kozin received a B.A. in Economics from Duke University and an MBA from The Wharton School, University of Pennsylvania.
Dr. Robert Langer is an award-winning Institute Professor at MIT. He has written more than 1,350 articles and has over 1,100 issued and pending patents worldwide. Dr. Langer has launched over 30 companies and his patents have been licensed to over 300 companies. He is one of the 10 most cited individuals, and the most cited engineer, in history. Dr. Langer has received over 220 major awards around the world, and is one of four living people to receive both the U.S. National Medal of Science and the U.S. National Medal of Technology and Innovation. He is also the only engineer to receive the Gairdner Foundation International Award, of which 82 recipients of this award have subsequently received a Nobel Prize. Dr. Langer completed his undergraduate studies in Chemical Engineering at Cornell University and obtained his Sc.D. in Chemical Engineering at MIT.